Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on June 22, 2020. The filing reports the entry into a material definitive agreement regarding clinical trial services.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific contract fees:
- Phase 2b Portion Fees: Approximately $60.0 million.
- Phase 3 Portion Fees: Approximately $41.3 million.
- Total Contract Value: Approximately $101.3 million.
Material Changes
On June 22, 2020, Galectin Therapeutics Inc. entered into a Second Work Order with Covance Inc. under a Master Services Agreement (MSA) originally signed on March 12, 2020. This agreement expands the scope of services to include the NASH-RX trial, an international, seamless, adaptively designed Phase 2b/3 trial.
Outlook, Risks, and Management Commentary
Management Commentary: The company is advancing its Phase 3 development program. The Second Work Order term expires upon completion of the services, unless terminated earlier per the MSA terms.
Risks and Contingencies: The filing notes that certain portions of the attached Work Order exhibit were omitted to prevent competitive harm. The agreement is subject to the terms and conditions set forth in the Second Work Order.
Investor Verification Checklist
- Verify the total committed capital required for the NASH-RX trial ($101.3 million) against current cash reserves.
- Review the full text of the Second Work Order (Exhibit 10.1) for termination clauses and payment milestones.
- Confirm the timeline for the Phase 2b and Phase 3 portions of the NASH-RX trial.
- Assess the impact of this expenditure on the company's runway and potential need for future capital raises.